Maybe the reason is that Samsung is already online
Post# of 148172
CYDY public announcements on manufacturing are materially different than the vaccince companies and other therapeutic companies. CYDY has publicly stated that Samsung can supply 1.2 million vials in 2020. That's 300,000 patients.
Is CYDY materially different than other vaccine and therapeutic providers in that CYDY capacity is already online?
Samsung brought the capacity online in anticipation of possible HIV product launch.
Samsung has already advertised that leronlimab is a $1 billion opportunity in 2020.
Regeneron needs $400 million to build a factory.
CYDY already has the Samsung factory online. All that's necessary is to increase the size of the purchase order.
Just a thought